Introduction: What Is Botulinum Toxin?
- 19 Downloads
Since its development for aesthetic use, botulinum toxin type A rapidly became one of the most popular cosmetic procedures. It is a fast minimally invasive and low-risk procedure, used with high efficacy in facial and non-facial indications.
Three commercial formulations are approved for cosmetic use, but they are not interchangeable. Dose equivalences between these formulations have been studied to provide similar results. The field of effects of all toxins is dose dependent.
Glabella was the first cosmetic indication approved by the regulatory agencies. Initially, only upper facial indications were targeted. Over time, middle and lower face indications and also non-facial indications started to be treated with successful results.
Proper technique, knowledge of facial anatomy, and correct evaluation of each individual’s characteristics are essential to obtain the best efficacious results. Non-cosmetic and cosmetic side effects may occur after the use of botulinum toxin type A. They are mostly technique related, mild, and transitory.
- 5.Scott AB, Rosenbaum A, Collins CC. Pharmacologic weakening of extraocular muscles. Investig Ophthalmol. 1973;12:924–7.Google Scholar
- 15.Heckmann M, Teichmann B, Schröder U, Sprengelmeyer R, Ceballos-Baumann AO. Pharmacologic denervation of frown muscles enhances baseline expression of happiness and decreases baseline expression of anger, sadness, and fear. J Am Acad Dermatol. 2003;49(2):213–6.PubMedCrossRefPubMedCentralGoogle Scholar
- 21.ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29 – Identifier NCT02939326, Evaluate safety and efficacy of a single treatment cycle of EB-001 in subjects with Glabellar Frown Lines; 2016 Oct 11 [cited 2017 Aug 21]; [about 5 screens]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT02939326?term=bonti&rank=2.
- 23.Karsai S, Raulin C. Current evidence on the unit equivalence of different botulinum neurotoxin A formulations and recommendations for clinical practice in dermatology. Dermatol Surg. 2009;35(1):1–8.Google Scholar
- 25.Carruthers J, Fournier N, Kerscher M, Ruiz-Avila J, Trindade de Almeida AR, Kaeuper G. The convergence of medicine and neurotoxins: a focus on botulinum toxin type A and its application in aesthetic medicine--a global, evidence-based botulinum toxin consensus education initiative: part II: incorporating botulinum toxin into aesthetic clinical practice. Dermatol Surg. 2013;39(3 Pt 2):510–25.PubMedCrossRefGoogle Scholar
- 36.Carruthers A, Carruthers J, Monheit GD, Davis PG, Tardie G. Multicenter, randomized, parallel-group study of the safety and effectiveness of onabotulinumtoxinA and hyaluronic acid dermal fillers (24-mg/mL Smooth, Cohesive Gel) alone and in combination for lower facial rejuvenation. Dermatol Surg. 2010;36:2121–34.PubMedCrossRefPubMedCentralGoogle Scholar
- 50.Carruthers J, Rivkin A, Donofrio L, et al. A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of repeated onabotulinumtoxinA treatments in subjects with Crow’s Feet Lines and Glabellar Lines. Dermatol Surg. 2015;41(6):702–11.PubMedCrossRefPubMedCentralGoogle Scholar